|
Reference:
1. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91(3):185-90.
2. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(1):16-26.
3. Khoza S, Moyo I, Ncube D. Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J Toxicol. 2017;2017:6746989.
4. U.S. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems [Internet]. 2016 [cited 2026 Feb 20]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially.
5. European Medicines Agency’s Committee on Medicinal Products for Human Use. Ketoconazole-containing medicines – referral [Internet]. 2016 [cited 2026 Feb 20]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/ketoconazole-containing-medicines.
Keywords:
เซ็บเดิร์ม, ketoconazole
|
|